Compare · NVNO vs SYK
NVNO vs SYK
Side-by-side comparison of enVVeno Medical Corporation (NVNO) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVNO and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 20425.9x NVNO ($5.5M).
- Over the past year, NVNO is down 70.6% and SYK is down 22.8% - SYK leads by 47.8 points.
- SYK has been more active in the news (7 items in the past 4 weeks vs 1 for NVNO).
- SYK has more recent analyst coverage (25 ratings vs 0 for NVNO).
- Company
- enVVeno Medical Corporation
- Stryker Corporation
- Price
- $7.73+7.66%
- $294.69+0.46%
- Market cap
- $5.5M
- $112.48B
- 1M return
- -14.68%
- +5.16%
- 1Y return
- -70.57%
- -22.78%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 1
- 7
- Recent ratings
- 0
- 25
enVVeno Medical Corporation
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based devices to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and works as a replacement venous valve to reduce reflux and venous hypertension, as well as to restore proper directional blood flow back to the heart. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest NVNO
- enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
- enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series
- Director Duhay Francis sold $123 worth of shares (11 units at $11.21) as part of a pre-agreed trading plan, decreasing direct ownership by 0.47% to 2,351 units (SEC Form 4)
- enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
- enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
- JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
- SEC Form S-3 filed by enVVeno Medical Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical Corporation
- Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
- enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)